文献速递前列腺增生与排尿功能障碍前列腺癌

钬激光前列腺剜除术后前列腺特异性抗原监测的作用

The Role of Prostate Specific Antigen Monitoring after Holmium Laser Enucleation of the Prostate.
PubMed 文献 · J Urol · 2019-09-06

本研究基于1999至2018年印第安纳大学1,147例钬激光前列腺剜除术(HoLEP)患者数据库,分析术后55例因故前列腺穿刺活检结果。发现术后PSA>1 ng/ml或PSA密度>0.1 ng/ml²与高危前列腺癌显著相关,建议活检阈值应低于未行HoLEP患者。

要点

  • HoLEP术后PSA>1 ng/ml时,穿刺检出癌症概率94%,临床显著癌风险80%。
  • PSA密度>0.1 ng/ml²与癌症风险95%、临床显著癌风险88%相关。
  • PSA>5.8 ng/ml或PSA密度>0.17 ng/ml²时均与活检证实癌症相关。

核心结论

  • HoLEP术后PSA和PSA密度对前列腺癌风险具有高阳性预测价值。
  • HoLEP术后活检阈值应低于未行HoLEP患者。

研究设计与样本

  • 回顾性队列研究,查询印第安纳大学1999至2018年HoLEP数据库,纳入1,147例有术后PSA数据的患者,记录55例术后活检。

主要发现

  • 55例因故行经直肠超声引导前列腺穿刺活检,超过90%的活检病例发现癌症。
  • 活检时PSA>1 ng/ml者癌症检出概率94%,临床显著疾病风险80%。
  • PSA密度>0.1 ng/ml²与癌症风险95%、临床显著癌症风险88%相关。
  • PSA>5.8 ng/ml或PSA密度>0.17 ng/ml²均与活检证实癌症普遍相关。

关键数值与推荐

  • HoLEP术后PSA>1 ng/ml或PSA密度>0.1 ng/ml²应行前列腺活检。
  • PSA>5.8 ng/ml或PSA密度>0.17 ng/ml²与活检证实癌症普遍相关。

临床怎么用

  • HoLEP术后应监测PSA和PSA密度,采用低于常规人群的阈值进行活检。
  • PSA>1 ng/ml或PSA密度>0.1 ng/ml²的患者应接受前列腺活检以排除临床显著癌。
  • 转诊医生应知晓HoLEP术后前列腺癌风险阈值的显著变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate specific antigen screening for prostate cancer has recently been challenged due to poor sensitivity. In addition to prostate cancer, a number of conditions elevate prostate specific antigen, of which benign prostatic hyperplasia is most common. The objective of this study was to assess the positive predictive value of prostate specific antigen and prostate specific antigen density for prostate cancer risk following holmium laser enucleation of the prostate. MATERIALS AND METHODS: We queried an institutional review board approved database of holmium laser enucleation of the prostate performed at Indiana University from 1999 to 2018 to identify 1,147 patients with prostate specific antigen data available after holmium laser enucleation. A total of 55 biopsies after enucleation were recorded. Demographics, prostate specific antigen, prostate volume and oncologic details were analyzed. The primary outcome was biopsy proven prostate cancer. RESULTS: A total of 55 patients underwent transrectal ultrasound prostate biopsy for cause after holmium laser enucleation of the prostate. Cancer was identified in more than 90% of biopsied cases. Men with prostate specific antigen above 1 ng/ml at biopsy had a 94% probability of cancer detection and an 80% risk of clinically significant disease. Prostate specific antigen density above 0.1 ng/ml2 was associated with a 95% risk of cancer and an 88% risk of clinically significant cancer. Prostate specific antigen greater than 5.8 ng/ml or prostate specific antigen density greater than 0.17 ng/ml2 was universally associated with biopsy proven cancer. CONCLUSIONS: Prostate specific antigen and prostate specific antigen density have high positive predictive value for prostate cancer risk after holmium laser enucleation of the prostate. Thresholds for biopsy should be lower than in patients who do not undergo holmium laser enucleation. Those who undergo that procedure and have prostate specific antigen above 1 ng/ml or prostate specific antigen density above 0.1 ng/ml2 are at higher risk for harboring clinically significant disease and should undergo biopsy. Referring physicians should be aware of these significant risk shifts.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Abedali ZA, Calaway AC, Large T, et al. The Role of Prostate Specific Antigen Monitoring after Holmium Laser Enucleation of the Prostate. J Urol. 2019. PMID: 31487219. doi:10.1097/JU.0000000000000530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。